Transplantation Direct (Apr 2021)

Resuming Deceased Donor Kidney Transplantation in the COVID-19 Era: What Do Patients Want?

  • Amarpreet K. Thind, MBBS,
  • Hannah Beckwith, MB ChB,
  • Rakesh Dattani, MBBS,
  • Amrita Dhutia, MB ChB,
  • Sarah Gleeson, MB BCh, BAO,,
  • Paul Martin, BM BS,,
  • Louise Ryan, MB BCh, BAO,,
  • Rishana Shuaib, MBBS,,
  • Shuli Svetitsky, MD,
  • Frank J.M.F. Dor, MD, PhD,
  • Edwina A. Brown, DM (Oxon), BM BCh,
  • Michelle Willicombe, MD, MBBS,
  • on behalf of the ICHNT Renal COVID grou*

DOI
https://doi.org/10.1097/TXD.0000000000001126
Journal volume & issue
Vol. 7, no. 4
p. e678

Abstract

Read online

Background. The rapidly evolving novel coronavirus 2019 (COVID-19) pandemic bought many kidney transplant (KT) programs to a halt. Integral to resuming KT activity is understanding the perspectives of potential transplant candidates during this highly dynamic time. Methods. From June 1 to July 7, 2020, a telephone survey of KT candidates on the deceased donor waiting list at Imperial College Renal and Transplant Centre in West London was conducted. The survey captured ongoing COVID-19 exposure risks and patients’ views on waitlist (WL) reactivation and undergoing transplantation. Results. Two hundred seven responses were received. Of the respondents, 180 patients (87%) were happy to be reactivated onto the WL; with 141 patients (68%) willing to give consent to transplantation currently, while 53 patients (26%) felt unsure, and 13 patients (6%) would decline a KT. The vast majority of patients had no concerns. In the responses from those who were uncertain or who would decline a KT, concerns about COVID-19 infection and the need for reassurance from transplant units dominated. Universally patients wanted more information about COVID-19 infection risk with KT and the precautions being taken to reduce this risk. Conclusions. The majority of surveyed patients are in favor of reactivation and receiving a KT despite the ongoing COVID-19 pandemic. Reactivation of candidates cannot be assumed and should take an individualized approach, incorporating clinical risk with patient perspectives. Improved communication with KT candidates is highly requested.